← All trials
NCT06278402
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2023
- Primary completion
- Jan 6, 2024
- Completion date
- Jan 16, 2024
- First posted
- Feb 26, 2024
- Last posted
- Feb 26, 2024
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jinnah Postgraduate Medical CentreLead sponsor
- Jinnah Postgraduate Medical CentreSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.